Generic Name and Formulations:
Carisoprodol 350mg; tabs.
Mylan Specialty L.P.
Indications for SOMA:
Relief of acute, painful musculoskeletal conditions.
≥16yrs: 250mg–350mg 3 times daily and at bedtime. Max 2–3 weeks.
<16yrs: not recommended.
Renal or hepatic dysfunction. Drug abuse. Pregnancy (Cat.C). Nursing mothers.
Muscle relaxant (central).
Sedative effects potentiated by alcohol, other CNS depressants. May be potentiated by CYP2C19 inhibitors (eg, omeprazole, fluvoxamine). May be antagonized by CYP2C19 inducers (eg, rifampin, St. John's Wort).
Dizziness, drowsiness, headache, GI upset, rash, tachycardia, orthostatic hypotension; rare idiosyncratic reactions (see literature).
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis